AP Biosciences, Inc. is advancing next-generation CD137 bispecific antibody therapies for solid tumor immunotherapy.
 
At the Taiwan Immuno-Oncology Drug Development Forum, founder Dr. Jeng Her shared how AP Biosciences is differentiating its strategy—developing its own platform to avoid CD3-related safety issues and instead targeting CD137 for safer, more effective therapies.
 
Highlights
 

• Market Momentum: 11 FDA approvals in 3 years; 100+ licensing deals, some > $10B.
• Proprietary Platforms: 5 clinical candidates, including Phase 2 & 3 programs out-licensed to partners.
• Lead Asset AP203: Dual-targets PD-L1 + CD137, Phase 1 trial in Taiwan shows >50% Disease Control Rate at just 60mg.

 
AP Biosciences is showing how smart antibody design and early platform investment can unlock the future of immuno-oncology.